Overactive Bladder Treatment
Market Dynamics
High prevalence of overactive
bladder is expected to propel the Overactive
Bladder Treatment Market growth over the forecast period. Moreover,
increasing awareness about the importance of diagnosis and treatment of the
disease is a key factor leading to increase in number of patients treated for
overactive bladder.
Furthermore, increasing number of
drug development programs for overactive bladder is expected to fuel the overactive
bladder treatment market growth, by adding new drug in the market. Currently,
generic drugs such as cholinergic receptor inhibitors are available for
treatment of the condition. Therefore, development and approval of new drug
entity with better drug profile is expected to boost the market growth.
For instance, in 2018, Urovant
Sciences—a biopharmaceutical company that focuses on developing novel therapy
for urologic conditions—entered in phase III clinical trial for its drug
—Vibegron —an oral Beta-andrenergic agonist for indication of overactive
bladder treatment.
Furthermore, Taris Biomedical
LLC—entered phase II clinical trials for its drug candidate TAR-302 for the
treatment of overactive bladder. TAR 302 is a trospium chloride-based
continuous local therapy, which is expected to efficiently aid in treatment of
overactive bladder with few side effects.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2007
Key players operating in the
market are focused on development of combinational therapies. For instance, in
2017, Astellas Pharma, Inc. received supplemental New Drug Application (sNDA)
from FDA for conditional therapy of mirabegron and solifenacin succinate for
the treatment of urinary incontinence.
Overactive bladder is a common
medical condition where there is sudden urge of urination. Overactive bladder
is sometimes coupled with urine leakage, condition known as incontinence.
Millions of people across the globe suffers from overactive bladder and it is
more common in old age people.
Urine leakage and frequent
urination are the main symptoms of overactive bladder. The frequency of
urination in the patient is around eight times a day. Moreover, frequent
urination during sleep hours is common in such patients. Overactive bladder is
commonly diagnosed by tests such as urine culture, bladder scan, cystoscopy or
urodynamic testing.
Robust drug pipeline with drugs
in phase II and phase III clinical trials, soon expected to be in the market,
are expected to drive the overactive bladder treatment market growth. However,
alternate therapies such as the neuromodulation therapy which includes sacral
neuromodulation and percutaneous tibial nerve stimulation to deliver electric
impulse to nerve, are expected to hinder the overactive bladder treatment
market growth.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/overactive-bladder-treatment-market-2007
Overactive Bladder Treatment
Market - Regional Analysis
The global overactive bladder
treatment market is segmented into six regions that include, North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa. North America
overactive bladder treatment market holds dominant position amongst other
regions, owing to high prevalence of overactive bladder in the region. For
instance, according to the journal Current Bladder Dysfunction Reports, 2016
review, millions of people suffer from overactive bladder in the U.S. and
estimates continuous increase in cost of overactive bladder management.
However, increasing awareness about the disease in Asia Pacific regions is
expected to boost the regional Asia Pacific overactive bladder treatment market
growth in the region, over the forecast period at a fast rate.
Overactive Bladder Treatment
Market – Competitive Analysis
Key players operating in the
overactive bladder treatment market include, Janssen Pharmaceuticals Inc.,
Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc.
(subsidiary of Teva Pharmaceuticals), Alembic Pharmaceuticals Ltd., Pfizer
Inc., Astellas Pharma Inc., Endo International PLC, and Invagen Pharmaceuticals
Inc.
Key players operating in the
market are focusing on leveraging their expertise to develop novel treatment
therapies for the disease, to enhance their market share. For instance, in
2017, UroGen Pharma Ltd .a clinical-stage biopharmaceutical company in
collaboration with Allergan Pharmaceuticals International Limited entered in
phase II clinical trial for RTGel in combination with BOTOX, for overactive
bladder treatment. RTGel is a hydrogel-based proprietary formulation of UroGen
Pharma Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2007
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment